Glucosa Physan (Glucose Monohydrate)

Glucosa Physan is indicated for clinical situations where rapid intravenous glucose delivery is required to support metabolic needs.

• Treatment of acute hypoglycemia when oral glucose administration is not feasible.
• Component of parenteral nutrition regimens to supply carbohydrate calories.
• Energy supplementation during surgical procedures or anesthesia.
• Support for patients with prolonged fasting or inability to ingest food.
• Maintenance of blood glucose levels in critically ill patients receiving intensive care.
• Adjunctive therapy for patients undergoing dialysis who require glucose supplementation.

Glucosa Physan may be associated with a range of adverse reactions, most of which are related to its intravenous administration and the metabolic effects of glucose.

Common

• Transient hyperglycemia or elevated blood glucose levels.
• Local irritation or pain at the injection site.
• Mild electrolyte shifts, particularly sodium or potassium changes.
• Nausea or mild gastrointestinal discomfort.
• Temporary increase in serum osmolality.
• Mild headache associated with rapid glucose rise.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Allergic or anaphylactic reactions to excipients.
• Volume overload or pulmonary edema in patients receiving large volumes.
• Hypotension due to rapid infusion of large volumes.
• Metabolic acidosis in patients with impaired glucose utilization.
• Severe hyperglycemia leading to osmotic diuresis.

When using Glucosa Physan, clinicians should observe specific precautions to minimize risks associated with intravenous glucose administration and fluid loading.

• Verify patient’s blood glucose level before and during infusion.
• Adjust infusion rate in patients with diabetes or impaired glucose tolerance.
• Monitor electrolyte balance, especially sodium and potassium, during therapy.
• Assess fluid status to avoid volume overload in heart‑failure or renal‑insufficient patients.
• Use aseptic technique to prevent catheter‑related infections.
• Consider contraindications such as known hypersensitivity to formulation components.
• Document infusion volume and rate in the patient’s medical record for ongoing monitoring.

Glucosa Physan can interact with other agents administered intravenously, influencing glucose homeostasis or fluid balance.

Avoid

• Concurrent administration of high‑dose insulin without appropriate glucose monitoring.
• Co‑infusion of hyperosmolar solutions that may exacerbate hyperglycemia.
• Simultaneous infusion of calcium‑containing solutions, which may precipitate with glucose formulations.

Use with caution

• Diuretics that alter electrolyte levels, requiring close monitoring.
• Vasopressors that may affect peripheral perfusion during infusion.
• Total parenteral nutrition regimens, to avoid excessive carbohydrate load.
• Renal replacement therapies, as glucose may be cleared variably.
• Beta‑blockers, as they may mask symptoms of hypoglycemia during glucose infusion.
• Anticoagulants, because rapid glucose infusion can affect coagulation parameters.